Prostate cancer is the second leading cause of cancer mortality in men in the US.
Uncommon in men aged under 50 years.
Prostate-specific antigen and digital rectal examination are key diagnostic tools used in screening.
Management may be expectant or definitive.
In the US, overall 5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013).
A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years.
History and exam
Richmond Radiation Oncology Associates
Bon Secours Cancer Institute
TJW declares that he is the principal investigator of an R-21 NIH research grant investigating the tumour-mediated immune responses in African-American men with prostate cancer.
Department of Radiation Oncology
University of Texas MD Anderson Cancer Center
MSA declares that he has no competing interests.
Clinical Oncology Registrar
St Luke's Cancer Centre
Royal Surrey Hospital
EA has received consultation fees from the following organisations during the past 3 years: Blue Cross/Blue Shield Association, Sanofi-Aventis, Ferring Pharmaceuticals, Pfizer Corporation, American Urological Association, National Institutes of Health, Accreditation Council for Graduate Medical Education, Royal Hallamshire Hospital, Hartford County Medical Association. EA owns shares in Pfizer Pharmaceuticals, Johnson and Johnson, and General Electric Corporation.
UConn Medical Group
University of Connecticut Health Center
PA declares that he has no competing interests.
Use of this content is subject to our disclaimer